Recursion (NASDAQ: RXRX) has recently announced its updated pipeline guidance and partnership updates during its investor and R&D day. The company's CEO, Chris Gibson, highlighted the increasing adoption of AI/ML solutions in the drug discovery space and the significant advancements made by Recursion over the past decade.
One of the key highlights is the guidance on seven clinical trial readouts expected within approximately 18 months. These include various phases of data readouts for different conditions such as cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, advanced cancers, Clostridioides difficile infection, and fibrotic diseases. Additionally, the company has dozens of internal and partner programs in early stages, with the first LLM and causal model-driven programs entering the recursion pipeline.
Partnership updates include Bayer becoming the first beta-user of Recursion's Lowe LLm-orchestrated workflow software and the initiation of the first joint oncology project, which is expected to advance rapidly towards lead series nomination. Recursion is also on track to complete 25 unique multi-modal data packages for Bayer by the third quarter of 2024.
In terms of platform updates, Recursion has achieved significant milestones such as potential 90 times the amount of lab throughput over a manual approach in ADME industrialization, built its first genome-scale transcriptomics knockout map, and achieved high success rates in predicting compounds' outcomes in disease-relevant assays.
Recursion's mission is to decode biology and industrialize drug discovery through its Recursion Operation System (OS), a platform that leverages machine-learning algorithms to distill trillions of searchable relationships across biology and chemistry. The company commands massive experimental and computational scales, uniting technology, biology, chemistry, and patient-centric data to advance the future of medicine.
The company's focus on leveraging technology, vast datasets, and partnerships to advance drug discovery and industrialize the process underscores its commitment to innovation and its potential impact on the future of medicine. Following these announcements, the company's shares moved 5.5%, and are now trading at a price of $9.34. If you want to know more, read the company's complete 8-K report here.
